Cargando…

Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p

Endothelial dysfunction (ED) causes worse prognoses in heart failure (HF) patients treated with cardiac resynchronization therapy (CRTd). ED triggers the downregulation of microRNA-130 (miR-130a-5p), which targets endothelin-1 (ET-1). Thus, we evaluated ED and the response to CRTd by assessing miR-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sardu, Celestino, Santulli, Gaetano, Savarese, Gianluigi, Trotta, Maria Consiglia, Sacra, Cosimo, Santamaria, Matteo, Volpicelli, Mario, Ruocco, Antonio, Mauro, Ciro, Signoriello, Giuseppe, Marfella, Lorenza, D’Amico, Michele, Marfella, Raffaele, Paolisso, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861580/ https://www.ncbi.nlm.nih.gov/pubmed/36675028 http://dx.doi.org/10.3390/ijms24021510

Ejemplares similares

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
por: Sardu, Celestino, et al.
Publicado: (2018)

Modulation of SERCA in Patients with Persistent Atrial Fibrillation Treated by Epicardial Thoracoscopic Ablation: The CAMAF Study
por: Sardu, Celestino, et al.
Publicado: (2020)

Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators
por: Sardu, Celestino, et al.
Publicado: (2020)

Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome
por: Sardu, Celestino, et al.
Publicado: (2017)

Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes
por: Sardu, Celestino, et al.
Publicado: (2017)

ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial
por: Sardu, Celestino, et al.
Publicado: (2018)

Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome
por: Sardu, Celestino, et al.
Publicado: (2018)

SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis
por: Sardu, Celestino, et al.
Publicado: (2023)

Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19
por: Sardu, Celestino, et al.
Publicado: (2020)

Evidence for human diabetic cardiomyopathy
por: Marfella, Raffaele, et al.
Publicado: (2021)

Implications of ABO blood group in hypertensive patients with covid-19
por: Sardu, Celestino, et al.
Publicado: (2020)

Implications of AB0 blood group in hypertensive patients with covid-19
por: Sardu, Celestino, et al.
Publicado: (2020)

Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes
por: Sardu, Celestino, et al.
Publicado: (2016)

Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts
por: Marfella, Raffaele, et al.
Publicado: (2022)

Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms
por: Sardu, Celestino, et al.
Publicado: (2022)

SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes
por: Marfella, Raffaele, et al.
Publicado: (2023)

Could Anti‐Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID‐19 Infection? Data From Centers of Southern Italy
por: Sardu, Celestino, et al.
Publicado: (2020)

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence
por: Sardu, Celestino, et al.
Publicado: (2020)

Circulating MiRNA-195-5p and -451a in Transient and Acute Ischemic Stroke Patients in an Emergency Department
por: Giordano, Mauro, et al.
Publicado: (2019)

Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation
por: Sardu, Celestino, et al.
Publicado: (2014)

SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells
por: D'Onofrio, Nunzia, et al.
Publicado: (2023)

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
por: Sardu, Celestino, et al.
Publicado: (2021)

COVID-19 and Its Cardiovascular Effects: Risk Factors, Prevention and Management
por: Sardu, Celestino, et al.
Publicado: (2023)

Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis
por: Marfella, Raffaele, et al.
Publicado: (2018)

Awaking Blood Pressure Surge and Progression to Microalbuminuria in Type 2 Normotensive Diabetic Patients
por: Barbieri, Michelangela, et al.
Publicado: (2016)

Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction
por: Sardu, Celestino, et al.
Publicado: (2021)

SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction
por: Marfella, Raffaele, et al.
Publicado: (2021)

Correction to: Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up
por: Sardu, Celestino, et al.
Publicado: (2018)

Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up
por: Sardu, Celestino, et al.
Publicado: (2018)

Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism?
por: Fontanella, Rosaria Anna, et al.
Publicado: (2021)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
por: Sardu, Celestino, et al.
Publicado: (2021)

Serum adiponectin levels are associated with worse cognitive function in postmenopausal women
por: De Franciscis, Pasquale, et al.
Publicado: (2017)

Editorial: Hyperglycemia and Coronary Artery Diseases: Physio-Pathological Findings and Therapeutic Implications
por: Marfella, Raffaele, et al.
Publicado: (2022)

Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin
por: Sardu, Celestino, et al.
Publicado: (2019)

Hyperglycaemia on admission to hospital and COVID-19
por: Sardu, Celestino, et al.
Publicado: (2020)

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
por: Sardu, Celestino, et al.
Publicado: (2020)

COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells
por: Jankauskas, Stanislovas S., et al.
Publicado: (2023)

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
por: Rizzo, Maria Rosaria, et al.
Publicado: (2012)

Response to Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082
por: Rizzo, Maria Rosaria, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_m59el5k3kbglsnkbe3rm6q9k3f